GlobeNewswire by notified

Ageas announces the payment of final instalments in the Fortis settlement

Share

Ageas announces the payment of final instalments in the Fortis settlement

Ageas announces today that it has decided, in agreement with the claimant organisations, to close the Fortis settlement enabling the claims administrator to proceedto the payment of final instalments.

Initially final calculations for all claimants and payment of final instalments would only be made after the very last dispute has been resolved. However, as only a very limited number of claims are still pending before Computershare (the independent claims administrator) or the Dispute Committee, Ageas did not want to let this limited number of unresolved claims keep some 279,000 other claimants waiting any longer.
Therefore, Ageas decided to bear the residual risk of these unresolved claims on top of the EUR 1.3 billion budget provided in the Settlement Agreement. This allows the claims administrator to proceed to the payment of the final instalments and thereby close the Fortis settlement for almost all claimants.

As significantly more claims were filed than expected, some components of a claimant’s Provisional Claim Amount will be subject to dilution.

In determining the final payment percentages mentioned below, the unresolved claims are deemed to be rejected, which maximizes the pay-out amounts for all other claimants within the foreseen budget of EUR 1.3 billion.
The resulting payment percentages are applied to the corresponding compensation component of a claimant’s Provisional Claim Amount to calculate a claimant’s Final Claim Amount:

  • Buyer Shares:                                        100%
  • Holder Shares:                                       77.48%
  • Compensation Add-On:                          61.62%
  • Cost Addition for Active Claimants:        120%

Given that fewer claims for Buyer Shares were filed than expected, buyers of Fortis Shares will receive 100% of the Buyer Share component of their Provisional Claim Amount.

Even after adding the excess funds of EUR 198.3 million transferred from the Buyer Shares bucket to the Holder Shares bucket, the pay-out percentage for Holder Shares is diluted to 77.48%.

For Active Claimants, the Cost Addition component will be increased up to the maximum of 120% provided for in the approved distribution plan.

The Compensation Add-On is most affected by the high number of claims filed, yielding a pay-out percentage of 61.62%.

A claimant’s final instalment will be the positive difference between the claimant’s Final Claim Amount and the instalment(s) already received. For non-Active Claimants whose compensation is primarily or exclusively composed of Compensation Add-On and/or Holder Shares the final instalment may be limited or zero. “Early filers” benefitted from a guaranteed pay-out of 70% of their Provisional Claim Amount and they may keep any overpayment if their Final Claim Amount is lower than the 70% of their Provisional Claim Amount they received as a first instalment.

In the days following 23 June 2022 each claimant with an accepted claim will receive a letter with the claimant’s Final Claim Amount and the amount of the final instalment, if any, by email or by regular post. The final payment will normally follow on or about 25 August 2022.

Ageas kindly asks claimants to be patient and to refrain from calling or emailing the call centre to get info about their specific, individual claim before they have received their letter. Before such time the call centre will not yet have the details of their Final Claim Amount. The call centre can be reached by telephone Monday through Friday from 9:00 until 18:00 CET. Ageas advises claimants to first consult the FORsettlement website (www.forsettlement.com) if they have any questions about this communication.

“I want to express my gratitude to the many claimants who have been waiting so patiently for closure and thank all organisations and persons involved in getting us to where we are today. With this decision Ageas again takes a major step, allowing the Group to fully focus on its business and to continue with the execution of its strategic plan Impact24.”
Hans De Cuyper, CEO Ageas

Ageas is a listed international insurance Group with a heritage spanning almost 200 years. It offers Retail and Business customers Life and Non-Life insurance products designed to suit their specific needs, today and tomorrow. As one of Europe's larger insurance companies, Ageas concentrates its activities in Europe and Asia, which together make up the major part of the global insurance market. It operates successful insurance businesses in Belgium, the UK, France, Portugal, Turkey, China, Malaysia, India, Thailand, Vietnam, Laos, Cambodia, Singapore, and the Philippines through a combination of wholly owned subsidiaries and long term partnerships with strong financial institutions and key distributors. Ageas ranks among the market leaders in the countries in which it operates. It represents a staff force of about 40,000 people and reported annual inflows close to EUR 40 billion in 2021 (all figures at 100%).

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date25.4.2024 07:30:00 CEST | Press release

Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide rapid access to US Veterans Health Administration Continued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its Full Year 2023 Financial and Operating Results. “In 2023, we made substantial progress against our objectives and laid the foundation to bring our ARC-EX System to the US market later this year,” said Dave Marver, CEO of ONWARD Medical. “We are off to a strong start again in 2024, raising EUR 20M in equity capital and submitting our De Novo application to the FDA for the ARC-EX System.” Full Year 2

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance25.4.2024 07:30:00 CEST | Press release

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performanceR&D expenses grew 11.8%, reflecting strategic shift of resources into developmentSG&A expenses grew 2.9%, less than sales growthBusiness EPS(1) of €1.78, down 17.6% reported and 7.4% at CERIFRS EPS of €0.91, down 43.1% reported R&D transformation advanced further Three regulatory approvals: new Dupixent indications in the US and Japan and Beyfortus in JapanPositive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare diseaseReaffirming increasing pipeline news flow over 2024-2

Huhtamäki Oyj’s Interim Report January 1–March 31, 2024: Improved operational profitability25.4.2024 07:30:00 CEST | Press release

HUHTAMÄKI OYJ INTERIM REPORT 25.4.2024 AT 8:30 EEST Q1 2024 in brief Net sales decreased 4% to EUR 1,004 million (EUR 1,047 million)Comparable net sales growth was -2% at Group levelReported EBIT was EUR 78 million (EUR 87 million); adjusted EBIT was EUR 99 million (EUR 92 million)Reported EPS was EUR 0.35 (EUR 0.47); adjusted EPS was EUR 0.55 (EUR 0.51)The impact of currency movements was EUR -17 million on the Group's net sales and EUR -2 million on EBIT Key figures EUR million Q1 2024 Q1 2023 Change 2023 Net sales 1,003.9 1,047.1 -4% 4,168.9 Comparable net sales growth -2% 2% -2% Adjusted EBITDA1 149.0 140.5 6% 590.1 Margin1 14.8% 13.4% 14.2% EBITDA 137.7 138.1 -0% 621.2 Adjusted EBIT2 98.8 92.1 7% 392.6 Margin2 9.8% 8.8% 9.4% EBIT 77.6 87.4 -11% 380.9 Adjusted EPS, EUR3 0.55 0.51 7% 2.32 EPS, EUR 0.35 0.47 -27% 1.97 Adjusted ROI2 11.5% 10.7% 11.2% Adjusted ROE3 13.3% 13.7% 13.2% ROI 10.7% 11.0% 10.9% ROE 11.0% 14.3% 11.8% Capital expenditure 36.6 65.2 -44% 318.7 Free Cash Flow 38.2

TRAINERS’ HOUSE GROUP INTERIM REPORT 1 JANUARY – 31 MARCH 202425.4.2024 07:30:00 CEST | Press release

TRAINERS' HOUSE GROUP, STOCK EXCHANGE RELEASE, 25 APRIL 2024 at 8:30 January-March 2024 in brief net sales EUR 2.3 million (EUR 2.8 million), change of -18.3 % compared to the corresponding period of the previous yearoperating result EUR 0.2 million (EUR 0.4 million), 7.3 % of net sales (14.5 %)cash flow from operations EUR 0.2 million (EUR 0.3 million)earnings per share EUR 0.08 (EUR 0.19) Key figures at the end of first quarter of 2024 cash and cash equivalents EUR 1.3 million (EUR 2.5 million)interest-bearing liabilities of EUR 0.8 million (EUR 0.4 million) and interest-bearing net debt of EUR -0.5 million (EUR -2.1 million).equity ratio 64.3 % (59.5 %) OUTLOOK FOR 2024 The company estimates the operating profit for 2024 to be negative. CEO ARTO HEIMONEN In the review period, acquiring new orders was challenging. The demand for services connected to overall well-being, mental growth and creating of meanings is growing. The sales of the company's personal training products strengthen

Flow Traders Q1 2024 Trading Update25.4.2024 07:30:00 CEST | Press release

Flow Traders Q1 2024 Trading Update Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited Q1 2024 trading update. Highlights Flow Traders recorded Net Trading Income of €127.1m and Total Income of €129.6m in Q124, compared to €72.7m and €74.3m, respectively, in Q423, and €110.5m for both in Q123. Flow Traders’ Value Traded increased 7% in Q124 when compared to last quarter and was flat when compared to the same period last year.Total Operating Expenses were €68.5m in Q124, compared to €62.5m in Q423 and €70.3m in Q123, with Fixed Operating Expenses of €43.6m, compared to €40.4m in Q423 and €43.9m in Q123.EBITDA was €61.1m in Q124, generating an EBITDA margin of 47%, compared to €11.8m and 16% in Q423 and €40.2m and 36% in Q123. Net Profit was €45.9m in Q124, yielding a basic EPS of €1.06, compared to €6.4m of Net Profit and €0.15 of basic EPS in Q423 and €27.7m and €0.64 in Q123. Trading capital stood at €609m at the end of Q124 and generated a 52% ret

HiddenA line styled icon from Orion Icon Library.Eye